Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44.2M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
35.8M
-
Shares change
-
+1.85M
-
Total reported value, excl. options
-
$74M
-
Value change
-
+$3.11M
-
Put/Call ratio
-
0.6
-
Number of buys
-
35
-
Number of sells
-
-26
-
Price
-
$2.07
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q3 2024
78 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q3 2024.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.8M shares
of 44.2M outstanding shares and own 80.96% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (10.9M shares), BAKER BROS. ADVISORS LP (10.1M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.77M shares), Boxer Capital, LLC (1.71M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.1M shares), BlackRock, Inc. (1.06M shares), VANGUARD GROUP INC (1.02M shares), ExodusPoint Capital Management, LP (922K shares), Avidity Partners Management LP (890K shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (550K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.